Rosuvastatin methyl ester
[CAS# 147118-40-9]

Identification

• Classification: API >> Circulatory system medication
• Name: Rosuvastatin methyl ester
• Synonyms: 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-(N-methyl-N-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid methyl ester
• Molecular Formula: C₂₃H₃₀FN₃O₆S
• Molecular Weight: 495.57
• CAS Registry Number: 147118-40-9
• EC Number: 604-568-6
• SMILES: CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)OC)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H317-H413
• Safety Statements: P261-P264-P270-P272-P273-P280-P301+P317-P302+P352-P321-P330-P333+P317-P362+P364-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H302
Skin sensitization	Skin Sens.	1	H317
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413

Discovery and Applications

Rosuvastatin methyl ester is a derivative of rosuvastatin, a widely used statin for lowering cholesterol. This compound was discovered through research efforts aimed at improving the pharmacokinetic properties and bioavailability of rosuvastatin. The methyl ester form was synthesized to investigate potential modifications that could enhance its therapeutic profile. Researchers focused on esterification to understand how altering the molecular structure could impact the drug's absorption, distribution, metabolism, and excretion (ADME) properties.

Rosuvastatin methyl ester is primarily explored for its potential in managing hypercholesterolemia. As a derivative of rosuvastatin, it aims to inhibit HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. By lowering low-density lipoprotein (LDL) cholesterol levels, this compound could help reduce the risk of cardiovascular diseases such as heart attack and stroke. The ester form might offer improved bioavailability, allowing for lower dosages or reduced dosing frequency.

One of the significant advantages of developing rosuvastatin methyl ester is its potential role in novel drug formulations. The esterification process can improve the lipophilicity of the molecule, enhancing its absorption through the gastrointestinal tract. This property makes it an attractive candidate for creating more efficient oral dosage forms.

Rosuvastatin methyl ester serves as a valuable tool in pharmacokinetic and pharmacodynamic studies. By comparing the ADME profiles of the ester form with those of the parent compound, researchers can gain insights into how structural modifications impact drug behavior in the body.

The enhanced properties of rosuvastatin methyl ester may make it suitable for combination therapy. Combining this compound with other lipid-lowering agents or antihypertensive drugs could provide a synergistic effect, offering more comprehensive cardiovascular protection.

Future research on rosuvastatin methyl ester could focus on its long-term safety and efficacy in clinical settings. Clinical trials are necessary to determine whether the theoretical benefits observed in preclinical studies translate to real-world patient outcomes. Moreover, exploring its effects in various populations, including those with comorbidities such as diabetes or metabolic syndrome, will be essential for understanding its full therapeutic potential.

References

2006. Rosuvastatin calcium. Pharmaceutical Substances.
URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-18-0052